Sandoz Group AG

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar business growing 21% in constant currencies  All regions contributing to growth Acquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the first quarter 2024.

Sandoz reports first quarter 2024 sales

All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board members Dividend of CHF 0.45 per registered dividend-paying share approved, representing 24% of core net income Basel, April 30, 2024 – Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2023 financial year. The shareholders in attendance, together with the votes represented by the independent proxy, represented 79.23% of registered shares.

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Amgen

Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.

Sandoz reaches agreement with Amgen over patent dispute

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on May 31, 2025 or earlier under certain circumstances Jubbonti® and Wyost® are first and only FDA-approved biosimilars to and interchangeable with Prolia*® and Xgeva*® Anticipated launch further strengthens Sandoz biosimilar portfolio and advances growth strategy Basel, April 30, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars.

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces that the European Commission (EC) has granted marketing authorization for Pyzchiva®* (biosimilar ustekinumab), developed and registered by Samsung Bioepis.

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production of one billion more penicillin tablets and doubling of output for key pediatric formulation Latest investment follows commissioning of EUR 150m antibiotic active ingredient facility -- on stream since November 2023 Basel, March 21, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe. The new facility and automated production lines will increase production capacity by 20% compared to the current capacity of 200 million packages per year.

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion, up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit growth in biosimilars both in the fourth quarter and full year Full-year 2023 core EBITDA margin of 18.1%, with strong contribution from net sales offset by expected inflation and standalone costs, and foreign exchange headwinds of 1.7 percentage points Full-year 2023 EBITDA margin of 9.5%, due to legal settlements, one-time separation costs and rationalization of specific manufacturing sites 2024 guidance of mid-single digit net sales growth in constant currencies and core EBITDA margin around 20% Basel, March 13, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the fourth quarter and results for the full year ended December 31, 2023.

Sandoz reports fourth quarter 2023 sales and full-year 2023 results

MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines. Keren Haruvi, President Sandoz North America, said: "Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events, which are disease states that can profoundly reduce quality of life for patients.

Sandoz receives FDA approval for first and only denosumab biosimilars

Sandoz shares fell after the company said its finance chief would retire at the end of June, news that came as a surprise to some analysts.

Sandoz Stock Hit by CFO Departure

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of Directors Colin Bond to retire as CFO of Sandoz on June 30, 2024 Basel, March 5, 2024 - The Board of Directors of Sandoz announced today that it proposes Mathai Mammen, M.D.

Sandoz announces nominations to the Board of Directors and leadership change

MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product launches.

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.

Sandoz enters $265 mln settlement agreement in U.S. price-fixing case

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules  MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs' claims in this litigation, if approved by Court Basel, February 29, 2024 – Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. (together, “Sandoz US”) – both indirect subsidiaries of Sandoz Group AG – have entered into a settlement agreement with the class of direct purchaser plaintiffs in the multidistrict litigation entitled In re Generic Pharmaceuticals Pricing Antitrust Litigation in the US District Court for the Eastern District of Pennsylvania.

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.  Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication of the financial statements 2023 Basel, February 1, 2024 - The Board of Directors of Sandoz announced today that it proposes Graeme Pitkethly for election to its Board of Directors at the company's next Annual General Meeting on April 30, 2024.

Sandoz announces changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE             Tyruko® approved for all indications of reference medicine             Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS)             Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1.

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million.

Sandoz to buy eye drug Cimerli in $170 million deal

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc. for an upfront cash purchase payment of USD 170 million.

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 92.6 million euros ($100.6 million), the South African company said on Monday.

South Africa's Aspen Pharmacare to buy Sandoz's China business

Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today.

Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care

Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the $208 billion (and increasing) global off-patent medicines market. Sandoz expects its EBITDA margin to increase from 18-19% in 2023 to 24-26% by 2028, driving significant improvements in profitability.

Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028

Basel, November 10, 2023 – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN  Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million Maturities of 3.5, 6.5 and 10 years, carrying fixed coupons at 3.97%, 4.22% and 4.50%, respectively Proceeds to repay bridge loan facility and for general corporate purposes Basel, November 8, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of three highly successful inaugural Eurobonds, with total gross proceeds of EUR 2.0 billion. Following a debut transaction in CHF last month, this issuance marks the entry of Sandoz into the EUR debt capital market.

Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds

Basel, October 26, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.

Sandoz successfully issues CHF 750 million in inaugural bonds

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz® launch, approval of Tyruko® in US and Europe, partnership on ustekinumab and closing of Mycamine® acquisition Full-year 2023 guidance confirmed Sandoz successfully listed on SIX Swiss Exchange as independent company on October 4 Basel, October 24, 2023 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced its year-to-date sales for the first nine months of 2023, with net sales up 6 percent in constant currencies (cc) to reach USD 7.1 billion.

News for Sandoz Group AG Stock (SDZNY)